Maxim Group set a $6.00 target price on Athersys (NASDAQ:ATHX) in a research report report published on Tuesday morning, Marketbeat Ratings reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Separately, ValuEngine raised shares of Athersys from a sell rating to a hold rating in a research note on Wednesday, November 22nd.

Shares of Athersys (ATHX) opened at $1.61 on Tuesday. Athersys has a one year low of $1.08 and a one year high of $2.63.

In related news, COO William Lehmann, Jr. sold 14,000 shares of the business’s stock in a transaction on Tuesday, December 19th. The shares were sold at an average price of $1.80, for a total value of $25,200.00. Following the sale, the chief operating officer now owns 503,712 shares of the company’s stock, valued at $906,681.60. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In the last three months, insiders sold 29,000 shares of company stock worth $51,075. 9.40% of the stock is currently owned by insiders.

Institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC bought a new stake in shares of Athersys in the fourth quarter worth $108,000. Thompson Davis & CO. Inc. grew its stake in shares of Athersys by 743.9% in the third quarter. Thompson Davis & CO. Inc. now owns 64,303 shares of the biopharmaceutical company’s stock worth $132,000 after purchasing an additional 56,683 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Athersys by 345.5% in the second quarter. The Manufacturers Life Insurance Company now owns 88,561 shares of the biopharmaceutical company’s stock worth $134,000 after purchasing an additional 68,680 shares during the last quarter. Rhumbline Advisers grew its stake in shares of Athersys by 34.2% in the second quarter. Rhumbline Advisers now owns 110,064 shares of the biopharmaceutical company’s stock worth $166,000 after purchasing an additional 28,030 shares during the last quarter. Finally, OxFORD Asset Management LLP bought a new stake in shares of Athersys in the third quarter worth $178,000. 20.20% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Athersys (ATHX) PT Set at $6.00 by Maxim Group” was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://theolympiareport.com/2018/02/14/athersys-athx-pt-set-at-6-00-by-maxim-group.html.

About Athersys

Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.